Why the study?
Coxsackievirus B3 infection causes inflammation-related diseases including viral myocarditis, but no vaccines or drugs have been approved for prevention or therapy.
Luteolin inhibits CVB3 replication and inflammation in vitro, suggesting it may be a potential therapeutic agent for CVB3-induced diseases such as viral myocarditis.
Answers are grounded in this paper and cite their sources.
Does not support clinical use in viral myocarditis; leaves open further development of luteolin against CVB3.
Coxsackievirus B3 (CVB3) infection causes many inflammation-related diseases, such as viral myocarditis and aseptic meningitis. However, no vaccines or drugs have been approved for prevention or therapy of CVB3-induced diseases. In this study, luteolin (3,4,5,7-tetrahydroxyflavone) had been found that could dose-dependently reduce the production of viral progeny and synthesis of CVB3 RNA and protein. The luteolin-mediated inhibition of CVB3 was found to be mechanistically possible, at least in part, through depressing the phosphorylation of p38 MAPK and JNK MAPK, and inhibiting NF-κB nuclear translocation and subsequently attenuated the expression of inflammatory cytokines in CVB3-infected cells. Luteolin may be a potential agent or supplement against CVB3 infection by inhibiting inflammation.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: